iCell Gene Therapeutics — Biomedical Watch V2

Traitements4programmes

Essais2liés

Publications0liées

SourceDBlocale

Traitements

4

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
CD19 CARvac T cellsThis is a phase I, interventional, single arm, open label, treatment study to evaluate the safety and tolerability of CD19 CARvac in patients with relapsed and/or refractory B cell malignancies.	SEP	Phase 1	Immunomodulation	China	À vérifier
ICG318, BCMA-CD19-IL-15/IL-15 sushi Compound CAR T following lymphodepletionThis Phase IIa, open-label, single-arm study includes an initial Safety Run-In followed by dose expansion to evaluate the safety, tolerability, cellular kinetics, pharmacodynamics, and preliminary clinical activity of a single infusion of ICG318 in participants with refractory SLE, with or without LN. Participants will receive protocol-specified lymphodepletion followed by ICG318 at the recommended Phase 2 dose.	Lupus	Phase 2	À vérifier	United States	À vérifier
ICG318, BCMA-CD19-IL-15/IL-15 sushi Compound CAR T following lymphodepletionThis Phase IIa, open-label, single-arm study includes an initial Safety Run-In followed by dose expansion to evaluate the safety, tolerability, cellular kinetics, pharmacodynamics, and preliminary clinical activity of a single infusion of ICG318 in participants with refractory SLE, with or without LN. Participants will receive protocol-specified lymphodepletion followed by ICG318 at the recommended Phase 2 dose.	Lupus	Phase 2	Thérapie cellulaire	United States	À vérifier
CD19 CARvac T cellsThis is a phase I, interventional, single arm, open label, treatment study to evaluate the safety and tolerability of CD19 CARvac in patients with relapsed and/or refractory B cell malignancies.	SEP	Phase 1	Immunomodulation	China	À vérifier

Essais cliniques

2

Molécule	Indication / population	Phase	NCT	Titre	Statut
CD19 CARvac T cells	SEP	Phase 1	NCT04156243	CD19 CARvac T Cells for Patients With Relapsed / Refractory B Cell Malignancies	UNKNOWN
ICG318, BCMA-CD19-IL-15/IL-15 sushi Compound CAR T following lymphodepletion	Lupus	Phase 2	NCT07328581	A Phase IIa Study of ICG318 CAR-T in Refractory Systemic Lupus Erythematosus With or Without Lupus Nephritis	RECRUITING

Publications

0

Molécule	Indication / population	Titre	Journal	Date
Aucune publication.